IL-31

IL-31 pathway may lead to new treatments for pruritusIn early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.
IL-31 at center stageA novel interleukin (IL) antagonist currently in phase 2 studies could advance the treatment of atopic dermatitis (AD), according to dermatologist.